Advanced search
Publication Cover
Biomarkers in Medicine Volume 1, 2007 - Issue 4
Submit an article Journal homepage
1,324
Views
0
CrossRef citations to date
0
Altmetric
Editorial

HIV-1 Tropism

George Panos1 Chelsea & Westminster Hospital,St Stephen‘s Centre,369 Fulham Road,London,SW10 9NH,UK.Correspondencegeorge.panos@[email protected] mark.nelson@[email protected]
&
Mark Nelson1 Chelsea & Westminster Hospital,St Stephen‘s Centre,369 Fulham Road,London,SW10 9NH,UK.Correspondencegeorge.panos@[email protected] mark.nelson@[email protected]
Pages 473-481 | Published online: 17 Dec 2007

Bibliography

  • Olsen WC , DoshanH, ZhanCet al.: Prolonged coating of CCR5 lymphocytes by PRO 140, a humanized CCR5 monoclonal antibody for HIV-1 therapy. Presented at: 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, USA, 5–8 February 2006, Abstract 515.
  • Olsen WC , NagashimaK, RosenfieldS, MaddonP: Potent synergistic inhibition of HIV-1 by combinations of the viral entry inhibitors PRO542 and T-20. Presented at: 40th (ICAAC) Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, ON, Canada, 17–20 September 2000, Abstract 549.
  • Jacobson JM , IsraelRJ, LowyIet al.: Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO542. Antimicrob. Agents Chemother.48, 423–429 (2004).
  • Norris D , MoralesJ, GodofskyEet al.: TNX-355, in combination with optimized background regimen (OBR), achieves statistically significant viral load reduction and CD4 cell count increase when compared with OBR alone in Phase 2 study at 48 weeks. Presented at: XVI International AIDS Conference. Toronto, Canada, 13–18 August 2006, Abstract THLB0218.
  • Moyle GE , DeJesusM, BoffitoRet al.: CXCR4 antagonism: proof of activity with AMD11070. Presented at: 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, USA, 25–28 February 2007, Abstract 511.
  • Saag M , RosenkranzS, BeckerSet al.: Proof of concept of antiretroviral activity of AMD11070 (an orally administered CXCR4 entry inhibitor): results of the first dosing cohort a studied in ACTG protocol A5210. Presented at: 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, USA, 25–28 February 2007, Abstract 512.
  • Dorr P , WestbyM, DobbsSet al.: Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother.49(11), 4721–4732 (2005).
  • Dorr P , MacartneyM, RickettGet al.: UK-427, 857, a novel small molecule HIV entry inhibitor is a specific antagonist of the chemokine receptor CCR5. Presented at: 10th Conference on Retroviruses and Opportunistic Infections. Hynes Convention Center, Boston, MA, USA, 10–14 February 2003, Abstract 443.
  • Gulick RM , SuZ, FlexnerCet al.: Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS clinical trials group 5211. J. Infect. Dis.196(2), 304–312 (2007).
  • Clotet B , RaffiF, CooperDet al.: Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations. AIDS18(8), 1137–1146, (2004).
  • Delmedico M , BrayB, CammackNet al.: Next generation HIV peptide fusion inhibitor candidates achieve potent, durable suppression of virus replication in vitro and improved pharmacokinetic properties. Presented at: 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, USA, 5–8 February 2006, Abstract 48.
  • Li F , Goila-GaurR, SalzwedelKet al.: PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc. Natl Acad. Sci. USA100(23), 13555–13560 (2003).
  • Feng Y , BroderC, KennedyP, BergerE: HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane G protein-coupled receptor.Science272, 872–877 (1996).
  • Dragic T , LitwinV, AllawayGet al.: HIV-1 entry into CD4R cells is mediated by the chemokine receptor CC-CKR-5. Nature381, 667–673 (1996).
  • Deng H , LiuR, EllmeierWet al.: Identification of a major co-receptor for primary isolates of HIV-1. Nature381, 661–666 (1996).
  • Berger E , DomsR, FenyöEet al.: A new classification for HIV-1. Nature391, 240 (1998).
  • Tersmette M , de GoedeR, AlBIet al.: Differential syncytium-inducing capacity of HIV isolates: frequent detection of syncytium-inducing isolates in patients with AIDS and AIDS-related complex.J. Virol.62, 2026–2032 (1988).
  • Bozzette S , McCutchanJ, SpectorS, WrightB, RichmanD: A cross-sectional comparison of persons with syncytium- and non-syncytium-inducing HIV.J. Infect. Dis.168, 1374–1379 (1993).
  • Koot M , KeetI, VosA, de GoedeR, RoosM, CoutinhoR: Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4R cell depletion and progression to AIDS.Ann. Intern. Med.118, 681–688 (1993).
  • Spijderman I , de WolfF, LangendamM, SchuitemakerH, CoutinhoR: Emergence of syncytium-inducing HIV type 1 variants coincides with a progression to AIDS.J. Infect. Dis.178, 397–403 (1998).
  • Hoffman T , DomsRW: Chemokines and coreceptors in HIV/SIV host interactions.AIDS, 12(Suppl. A), S17–S26 (1998).
  • Jekle A , KepplerOT, De ClercqE, ScholsD, WeinsteinM, GoldsmithMA: In vivo evolution of human immunodeficiency virus type 1 toward increased pathogenicity through CXCR4-mediated killing of uninfected CD4 T cells.J. Virol.77, 5846–5854 (2003).
  • Tersmette M , GrutersRA, de WolfFet al.: Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates.J. Virol.63, 2118–2125 (1989).
  • Tersmette M , LangeJM, de GoedeREet al.: Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality. Lancet1(8645), 983–985 (1989).
  • Zaitseva M , LeeS, RabinRet al.: CXCR4 and CCR5 on human thymocytes: biological function and role in HIV-1 infection. J. Immunol.161, 3103–3113 (1998).
  • Correa R , Munoz-FernandezMA: Viral phenotype affects the thymic production of new T cells in HIV-1-infected children.AIDS15, 1959–1963 (2001).
  • Malkevitch N , McDermottD, YiJet al.: Coreceptor choice and T cell depletion by R5, X4, and R5X4 HIV-1 variants in CCR5-deficient (CCR5D32) and normal human lymphoid tissue. Virology281, 239–247 (2001).
  • Hazemberg M , OttoS, HamannDet al.: Depletion of naive CD4 T cells by CXCR4-using HIV-1 variants occurs mainly through increased T-cell death and activation. AIDS17, 1419–1424 (2003).
  • Nishimura Y , BrownC, MattapallilJet al.: Resting naive CD4R T cells are massively infected and eliminated by X4-tropic simian-human immunodeficiency viruses in macaques. Proc. Natl Acad. Sci. USA102, 8000–8005 (2005).
  • Moyle GJ , WildfireA, MandaliaSet al.: Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J. Infect. Dis.191(6), 866–872 (2005).
  • Lalezari J , GoodrichJ, DeJesusEet al.: Efficacy and safety of maraviroc plus optimised background therapy in viremic ART-experienced patients infected with CCR5-tropic HIV-1: 24 week results from a Phase 2b/3 study in the US and Canada. Presented at: 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, USA, 25–28 February 2007, Abstract 104bLB.
  • Nelson M , FatkenheuerG, KonourinaIet al.: Efficacy and safety of maraviroc plus optimised background therapy in viremic ART-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia and North America: 24 week results. Presented at: 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, USA, 25–28 February 2007, Abstract 104aLB.
  • Lalezari J , MayerH: Efficacy and safety of maraviroc (MVC) in antiretroviral treatment-experienced patients infected with CCR5-tropic HIV-1: 48-week results of MOTIVATE 1. Presented at: 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17–20 September 2007.
  • Mayer H , van der RystE, SaagMetal.: Safety and efficacy of maraviroc (MVC), a novel CCR5 antagonist, when used in combination with optimized background therapy (OBT) for the treatment of antiretroviral-experienced subjects infected with dual/mixed-tropic HIV-1: 24 week results of a Phase 2b exploratory trial. Presented at: XVI International AIDS Conference. Toronto, Canada, 13–18 August 2006, Abstract THLB0215.
  • Schuitemaker H , KootM, KootstraNet al.: Biological phenotype of HIV type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus populations. J. Virol.66, 1354–1360 (1992).
  • Connor R , SheridanK, CeradiniD, ChoeS, LandayN: Change in coreceptor use coreceptor use correlates with disease progression in HIV-1-infected individuals.J. Exp. Med.185, 621–628 (1997).
  • Daar ES , KeslerKL, PetropoulosCJet al.: Baseline HIV type 1 coreceptor tropism predicts disease progression. 45(5), 643–649 (2007)
  • Labernardiere J , Lebel-BinayS, FaudonJL, HolguinA, SorianoV, CheretA: Tropism determination and performance of Phenoscript HIV-1 entry inhibitors assay.Antivir. Ther. (Lond.)9, S141 (2004).
  • Huang W , WrinM, YapJet al.: A rapid multi-functional HIV-1 entry assay for measuring drug susceptibility, co-receptor tropism, and antibody neutralization. Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. McCormick Place Lakeside Center, Chicago, IL, USA, 16–19 December 2001.
  • Westby M , WhitcombJ, HuangWet al.: Reversible predominance of CXCR4 utilizing variants in a non-responsive dual tropic patient receiving the CCR5 antagonist UK-427,857. Presented at: 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 8–11 February 2004, Abstract 538.
  • Kitrinos K , LaBrancheC, StanhopeM, MadsenH, DemarstJ: Clonal analysis detects pre-existing R5X4-tropic virus in a patient demonstrating populations-level tropism shift on 873140 monotherapy.Antivir. Ther. (Lond.)10(Suppl.), 68 (2005).
  • Kitrinos K , IrlbeckD, BonnyTet al.: HIV-1 co-receptor tropism in drug naive patients representing different HIV-1 subtypes tested in 2005. Presented at: 1st International Workshop on Targeting HIV Entry. Bethesda, MD, USA, 2–3 December 2005, Abstract 6.
  • Whitcomb J , HuangW, FransenSet al.: Development and characterisation of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob. Agents Chemother.51(2), 566–575 (2007).
  • Reeves JD , HanD, LiuYet al.: Enhancements to the Trofile HIV coreceptor tropism assay enable reliable detection of CXCR4-using subpopulations at less than 1%. Presented at: 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17–20 September 2007.
  • Stawiski E , WhitcombJ, CoakleyEet al.: Coreceptor tropism predictions based on V3 loop sequence in antiretroviral experienced patients are specific but incensitive for the detection of CXCR4-using variants. Presented at: 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17–20 September 2007.
  • Moncunill G , Armand-UgonM, ClotetBet al.: HIV-1 co-receptor switch induced by antagonism to CCR5. Presented at: 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, USA, 25–28 February 2007, Abstract 618.
  • Delobel P , Sandres-SaunéK, CazabatMet al.: R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr.38, 382–392 (2005).
  • Skrabal K , TrouplinV, LabrosseBet al.: Impact of antiretroviral treatment on the tropism of HIV-1 plasma virus populations. AIDS17, 809–814 (2003).
  • Galán I , JimenezJ, González-RiveraMet al.: Virological phenotype switches under salvage therapy with lopinavir-ritonavir in heavily pretreated HIV-1 vertically infected children. AIDS18, 247–255 (2004).
  • Johnston E , ZijenahL, MutetwaSet al.: High frequency of syncytium-inducing and CXCR4-tropic viruses among HIV type 1 subtype C-infected patients receiving antiretroviral treatment. J. Virol.77, 7682–7688 (2003).
  • Koot M , van LeeuwenR, de GoedeREet al.: Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis.J. Infect. Dis.179, 254–258 (1999).
  • Furrer H , WendlandT, MinderCet al.: Association of syncytium inducing phenotype of HIV-1 with CD4 cell count, viral load and sociodemographic characteristics. AIDS12, 1341–1346 (1998).
  • Bozzette SA , McCutchanJA, SpectorSA, WrightB, RichmanDD: A cross-sectional comparison of persons with syncytium- and non-syncytium-inducing human immunodeficiency virus.J. Infect. Dis.168, 1374–1379 (1993).
  • Waters LJ , MandaliaS, WildfireAet al.: CXCR4/mixed-tropic HIV-1 is associated with more rapid CD4 cell decline compared with CCR5-tropic virus in antiretroviral-naive individuals. Presented at: 46th Annual ICAAC Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 27–30 September 2006.
  • Begaud E , FeindirongaiG, VersmissePet al.: Broad spectrum of coreceptor usage and rapid disease progression in HIV-1-infected individuals from Central African Republic. AIDS Res. Hum. Retroviruses19(7), 551–560 (2003).
  • Casper C , NaverL, ClevestigPet al.: Coreceptor change appears after immune deficiency is established in children infected with different HIV-1 subtypes. AIDS Res. Hum. Retroviruses18(5), 343–352 (2002).
  • Pohlmann S , KrumbiegelM, KirchhoffF: Coreceptor usage of BOB/GPR15 and Bonzo/STRL33 by primary isolates of human immunodeficiency virus type 1.J. Gen.Virol.80(Pt 5), 1241–1251 (1999).
  • Tscherning-Casper C , VodrosD, MenuEet al.: Coreceptor usage of HIV-1 isolates representing different genetic subtypes obtained from pregnant Cameroonian women. European Network for In Utero Transmission of HIV-1. J. Acquir. Immune Defic. Syndr.24(1), 1–9 (2000).
  • Zerhouni-Layachi B , HusainM, RossMJet al.: Dual tropism of HIV-1 envelopes derived from renal tubular epithelial cells of patients with HIV-associated nephropathy. AIDS20(4), 621–624 (2006).
  • Cilliers T , WilleyS, SullivanWMet al.: Use of alternate coreceptors on primary cells by two HIV-1 isolates. Virology339(1), 136–144 (2005).
  • Tscherning C , AlaeusA, FredrikssonRet al.: Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virology241(2), 181–188 (1998).
  • Jansson M , BackstromE, BjorndanAet al.: Co-receptor usage and RANTES sensitivity of non-syncytium-inducing HIV-1 isolates obtained from patients with AIDS. J. Hum. Virol.2, 325–338 (1999).
  • Koning F , KwaD, Boeser-NunninkBet al.: Decreasing sensitivity to RANTES (regulated on activation, normally T cell-expressed and -secreted) neutralization of CC chemokine receptor 5-using, non-syncytium-inducing virus variants in the course of HIV type 1 infection. J. Infect. Dis.188, 864–872 (2003).
  • Karlsson L , AntonssonL, ShiYet al.: Co-evolution of RANTES sensitivity and mode of CCR5 receptor use by HIV type 1 of the R5 phenotype. J. Virol.78, 11807–11815 (2004).
  • Kwa D , VingerhoedJ, BoeserB, SchuitemakerH: Increased in vitro cytopathicity of CC chemokine receptor 5-restricted HIV type 1 primary isolates correlates with a progressive clinical course of infection.J. Infect. Dis.187, 1397–1403 (2003).
  • Gray L , SterjovskiJ, ChurchillMet al.: Uncoupling coreceptor usage of HIV-1 from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with AIDS. Virology337, 384–398 (2005).
  • Murga JD , FrantiM, PevearDCet al.: Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1. Antimicrob. Agents Chemother.50(10), 3289–3296 (2006).
  • Tremblay CL , GiguelF, ChouTC, DongH, TakashimaK, HirschMS: TAK-652, a novel CCR5 inhibitor, has favourable drug interactions with other antiretrovirals in vitro.Antivir. Ther.10, 967–968 (2005).
  • Tremblay CL , GiguelF, GuanY, ChouTC, TakashimaK, HirschMS: TAK-220, a novel small-molecule CCR5 antagonist, has favourable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro.Antimicrob. Agents Chemother.49, 3483–3485 (2005).
  • Tremblay CL , GiguelF, KollmannCet al.: Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro. Antimicrob. Agents Chemother.46, 1336–1339 (2002).
  • Dorr P , WestbyM, DobbsSet al.: Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother.49(11), 4721–4732 (2005).
  • Nagashima K , RosenfieldS, ThompsonDet al.: Mechanisms of synergy between HIV-1 attachment, coreceptor and fusion inhibitors. Presented at: 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, USA, 4–8 February 2001, Abstract 310.
  • Westby M , MoriJ, Smith-BurchnellCet al.: Maraviroc (UK-427,857)-resistant HIV-1 variants, selected by serial passage, are sensitive to CCR5 antagonists and T-20. Presented at: XIV International HIV Drug Resistance Workshop IC Report: Basic Principles and Clinical Implications. Québec City, Québec, Canada, 7–11 June 2005, Abstract 65 (poster).
  • Strizki JM , WojcikL, MarozsanAJet al.: Properties of in vitro generated HIV-1 variants resistant to the CCR5 antagonists SCH 351125 and SCH 417690. Presented at: XIV International HIV Drug Resistance Workshop IC Report: Basic Principles and Clinical Implications. Québec City, Québec, Canada, 7–11 June 2005, Abstract 59 (poster).
  • Ray N , HarrisonJE, BlackburnLAet al.: Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors. J. Virol.81(7), 3240–3250 (2007).
  • Delmedico M , BrayB, CammackNet al.: Next generation HIV peptide fusion inhibitor candidates achieve potent, durable suppression of virus replication in vitro and improved pharmacokinetic properties. Presented at: 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, USA, 5–8 February 2006, Abstract 48.
  • Glass WG , LimJK, CholeraR, PletnevAG, GaoJL, MurphyPM: Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection.J. Exp. Med.202(8), 1087–1098 (2005).
  • Lim JK , GlassWG, McDermottDH, MurphyPM: CCR5: no longer a ‘good for nothing‘ gene-chemokine control of West Nile virus infection.Trends Immunol.27(7), 308–312 (2006).
  • Diamond MS , KleinRS: A genetic basis for human susceptibility to West Nile virus.Trends Microbiol.14(7), 287–289 (2006).
  • Glass WG , McDermotDH, LimJKet al.: CCR5 deficiency increases risk of symptomatic West Nile virus infection. J. Exp. Med.203(1), 35–40 (2006).
  • Goulding C , McManusR, MurphyAet al.: The CCR5-D32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source. Gut54(8), 1157–1161 (2005).
  • Hellier S , FrodshamA, HenningBet al.: Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology38, 1468–1476 (2003).
  • Vincent T , PortalesP, BaillatVet al.: T-cell surface CCR5 density is not correlated with hepatitis severity in hepatitis C virus/HIV-coinfected individuals. J. Acquir. Immune Defic. Syndr.38, 305–309 (2005).
  • Wasmuth HE , WerthA, MuellerTet al.: CC chemokine receptor 5 D32 polymorphism in two independent cohorts of hepatitis C virus infected patients without hemophilia. J. Mol. Med.82(1), 64–69 (2004).
  • Woitas RP , AhlenstielG, IwanAet al.: Frequency of the HIV-protective CC chemokine receptor 5-D32/D32 genotype is increased in hepatitis C. Gastroenterology122(7), 1721–1728 (2002).
  • Thoelen I , VerbeeckJ, WollantsEet al.: Frequency of the CCR5D32 mutant allele is not increased in Belgian hepatitis C virus-infected patients. Viral Immunol.18(1), 232–235 (2005).
  • Tommasi AM , FabrisP, CarderiIet al.: Lack of higher frequency of the chemokine receptor 5-D32/D32 genotype in hepatitis C. J. Clin. Gastroenterol.40(5), 440–443 (2006).
  • Promrat K , McDermottDH, GonzalezCMet al.: Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology124(2), 352–360 (2003).
  • Ahlenstiel G , BergT, WoitasRPet al.: Effects of the CCR5-D32 mutation on antiviral treatment in chronic hepatitis C. J. Hepatol.39(2), 245–252 (2003).
  • Tsibris AMN , ParedesR, SuZet al.: Vicriviroc therapy and EBV plasma viral loads in HIV-1 infected treatment-experienced subjects. Presented at: 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, USA, 25–28 February 2007, Poster 844.
  • Skrabal K , TrouplinV, LabrosseBet al.: Impact of antiretroviral treatment on the tropism of HIV-1 plasma virus populations. AIDS17, 809–814 (2003).
  • Kulkosky J , PomerantzRJ: Approaching eradication of highly active antiretroviral therapy-persistent human immunodeficiency virus type 1 reservoirs with immune activation therapy.Clin. Infect. Dis.35, 1520–1526 (2002).
  • Johnson WE , DesrosiersRC: Viral persistance: HIV‘s strategies of immune system evasion.Annu. Rev. Med.53, 499–518 (2002).
  • Smith KA : To cure chronic HIV infection, a new therapeutic strategy is needed.Curr. Opin. Immunol.13, 617–624 (2001).
  • Lehrman G , HogueIB, PalmerSet al.: Depletion of HIV-1 infection in vivo: a proof of concept study.Lancet366, 549–555 (2005).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.